This Week
Last Week
This Month
Last Month
All days

The CIGB?s Health Impact

Health impact is considerable at the population level in many fields, for example hepatitis-B has disappeared in the infant population. Cuba does not only hope to eradicate this infectious disease in a few years, but also to eliminate the virus circulation. Additional relevant facts supply a picture of the CIGB health impact.
The hepatitis B vaccine manufactured at the CIGB has reduced the incidence of this infectious disease in Cuba from 376 cases in 1991 to eradication in 2000, it has been on the WHO?s list of vaccines purchased by UNO from 2001. $220 million worth of vaccine were sold in 10 years and 100 million doses have been used.
In clinical trials with the recombinant streptokinase manufactured at the CIGB, 86% efficacy was obtained for the treatment of prosthetic heart valve thrombosis and in acute myocardial infarction the rate of thrombolysis was around 50% and even 70% in some medical units.
Large-scale production of the first worldwide synthetic vaccine was made possible by the CIGB?s staff, a few months after the vaccine discovery. In clinical trials, 99.7% of the test infants reached antibody titres above those considered appropriate for long-lived protection against Haemophilus influenzae type b.
The recombinant humanised antibody against the epidermal growth factor receptor (EGF-R), now in clinical trials for cancer therapy in Cuba and other countries, was transiently expressed in tobacco leaves, correctly assembled and retaining its biological activity.
The Finlay Institute (FI), the CIGB and the Centre for Bioreagents, have overcome the huge challenge of supplying a safe tetravalent vaccine to the Cuban Immunization Program. The new combined vaccine Trivac-HB